VYNE Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

VYNE Therapeutics şirketinin kazançlarının yıllık 15.6% oranında düşmesi, yıllık gelirinin ise yıllık 64.5% oranında artması bekleniyor. EPS'nin yıllık 7.9% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-15.6%

Kazanç büyüme oranı

-7.90%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	14.4%
Gelir büyüme oranı	64.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	08 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jun 27

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.

Analiz Makalesi • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.

Analiz Makalesi • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...

Seeking Alpha • Jun 30

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VYNE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	7	-88	-121	N/A	2
12/31/2027	N/A	-66	-81	N/A	2
12/31/2026	N/A	-50	-56	N/A	2
3/31/2026	0	-22	-26	-26	N/A
12/31/2025	1	-27	-33	-33	N/A
9/30/2025	1	-34	-38	-38	N/A
6/30/2025	0	-39	-40	-40	N/A
3/31/2025	1	-42	-38	-37	N/A
12/31/2024	1	-40	-34	-34	N/A
9/30/2024	0	-34	-30	-30	N/A
6/30/2024	0	-28	-27	-27	N/A
3/31/2024	0	-29	-28	-28	N/A
12/31/2023	0	-28	-25	-25	N/A
9/30/2023	0	-29	-25	-25	N/A
6/30/2023	0	-33	-27	-27	N/A
3/31/2023	0	-31	-26	-26	N/A
12/31/2022	0	-34	-29	-29	N/A
9/30/2022	1	-35	-34	-34	N/A
6/30/2022	1	-40	-45	-45	N/A
3/31/2022	1	-42	-53	-53	N/A
12/31/2021	1	-44	-56	-56	N/A
9/30/2021	5	-59	-72	-72	N/A
6/30/2021	8	-69	-78	-78	N/A
3/31/2021	19	-226	-97	-97	N/A
12/31/2020	21	-256	-137	-137	N/A
9/30/2020	17	-270	-134	-134	N/A
6/30/2020	14	-269	-133	-132	N/A
3/31/2020	2	-120	-110	-109	N/A
12/31/2019	0	-95	N/A	-73	N/A
9/30/2019	1	-71	N/A	-62	N/A
6/30/2019	2	-64	N/A	-62	N/A
3/31/2019	3	-63	N/A	-62	N/A
12/31/2018	4	-74	N/A	-69	N/A
9/30/2018	4	-77	N/A	-70	N/A
6/30/2018	4	-80	N/A	-69	N/A
3/31/2018	4	-77	N/A	-64	N/A
12/31/2017	4	-66	N/A	-53	N/A
9/30/2017	4	-59	N/A	-53	N/A
6/30/2017	6	-47	N/A	-36	N/A
3/31/2017	6	-39	N/A	-32	N/A
12/31/2016	6	-29	N/A	-27	N/A
9/30/2016	4	-24	N/A	-18	N/A
6/30/2016	2	-21	N/A	-19	N/A
3/31/2016	1	-18	N/A	-18	N/A
12/31/2015	1	-17	N/A	-12	N/A
9/30/2015	4	-11	N/A	-10	N/A
6/30/2015	4	-16	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VYNE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: VYNE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: VYNE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: VYNE gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: VYNE gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VYNE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/21 09:31
Gün Sonu Hisse Fiyatı	2026/05/21 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

VYNE Therapeutics Inc. 11 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Douglas Tsao	Barclays
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Guggenheim Securities, LLC

VYNE Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to US$0.59 loss

Price target decreased by 11% to US$5.50

Consensus EPS estimates fall by 19%

Consensus revenue estimates increase by 250%

Consensus revenue estimates fall by 20%

Consensus EPS estimates fall by 13%

Recent updates

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.20 loss in 1Q 2025)

VYNE Therapeutics Inc. Receives an Additional 180 Calendar Days Extension to Regain Compliance with the Minimum Bid Price Requirement

Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. (NasdaqCM:VYNE) in a reverse merger transaction.

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Insufficient new directors

First quarter 2025 earnings released: US$0.20 loss per share (vs US$0.15 loss in 1Q 2024)

Consensus EPS estimates upgraded to US$0.59 loss

New major risk - Market cap size

Price target decreased by 11% to US$5.50

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Consensus EPS estimates fall by 19%

VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Consensus revenue estimates increase by 250%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

VYNE Therapeutics Provides Update on VYN202 Program

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00